<DOC>
	<DOCNO>NCT01511549</DOCNO>
	<brief_summary>Primary Objective : To assess safety tolerability SAR113945 Japanese patient knee osteoarthritis ascend single intra-articular dos Secondary Objective : To assess pharmacokinetics SAR113945 Japanese patient knee osteoarthritis ascend single intra-articular dos</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics SAR113945 Japanese Patients With Knee Osteoarthritis</brief_title>
	<detailed_description>Following single dose study medication , study period patient 168 day .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Inclusion criterion : Japanese male female patient , age 40 year old , knee osteoarthritis Diagnosis primary knee osteoarthritis , base upon follow : Xray magnetic response imaging ( MRI ) evidence within last 6 month joint space narrow osteophyte formation Patients Kellegen Lawrence classification II III , total Western Ontario McMaster ( WOMAC ) score equal 72 Patients fulfilling American College Rheumatology Clinical Radiographic criterion Osteoarthritis Exclusion criterion : Women child bear potential Secondary osteoarthritis : e.g. , autoimmune disease , joint dysplasia , aseptic osteonecrosis , acromegaly , Paget 's disease , EhlersDanlos syndrome , Gaucher 's disease , Stickler 's syndrome , joint infection , hemophilia , hemochromatosis , calcium pyrophosphate disposition disease , neuropathic arthropathy Presence local skin abnormality affect knee joint Any patient receive intraarticular injection within 3 month prior administration The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>